Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Open in API
Filings indexed 498 across all filing types
Latest filing 2020-07-23 Regulatory Filings
Country IN India
Listing BSE.NS BROOKS

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 70% confidence The document text is mostly unreadable or corrupted, containing mostly non-standard characters and no clear textual content. There are no identifiable keywords, regulatory references, report titles, fiscal periods, or any other indicators that would allow classification into a specific filing category. The document length is 3554 characters, which is relatively short and does not contain substantive financial data or report content. Given the lack of meaningful content and inability to classify it into any specific category, the best fit is the fallback category Regulatory Filings (RNS).
2020-07-23 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges informing about a scheduled Board of Directors meeting to consider and approve audited financial results for the quarter and fiscal year ended March 31, 2020. It also mentions the closure of the trading window for insiders. The document is dated July 22, 2020, and references SEBI regulations. The content is an announcement of an upcoming board meeting and trading window closure, not the financial results report itself. The document length is short (1972 characters) and it does not contain any financial data or results. Therefore, it is an announcement related to board meeting and trading window closure, which fits best under Board/Management Information (MANG).
2020-07-22 English
Outcome of Board Meeting
Regulatory Filings
2020-07-22 English
Outcome of Board Meeting
Regulatory Filings
2020-07-21 English
Board Meeting — Financial Results
Regulatory Filings
2020-07-13 English
Financial Results Updates
Regulatory Filings
2020-07-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.